miR-200b is a key regulator of tumor progression and metabolism targeting lactate dehydrogenase A in human malignant glioma

Su Hu; Qian Jiang; Dongdong Luo; Lei Zhao; Xin Fu; Yuqin Chen; Xue Song; Lihua Li; Hailin Zhao; Yingfang He; Biao Peng

doi:10.18632/oncotarget.10301

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

miR-200b is a key regulator of tumor progression and metabolism targeting lactate dehydrogenase A in human malignant glioma

Su Hu, Qian Jiang, Dongdong Luo, Lei Zhao, Xin Fu, Yuqin Chen, Xue Song, Lihua Li, Hailin Zhao, Yingfang He and Biao Peng _

PDF | HTML | How to cite

Oncotarget. 2016; 7:48423-48431. https://doi.org/10.18632/oncotarget.10301

Metrics: PDF 2123 views | HTML 2140 views | ?

Abstract

Su Hu1,*, Qian Jiang2,*, Dongdong Luo1, Lei Zhao3, Xin Fu2, Yuqin Chen2, Xue Song4, Lihua Li1, Hailin Zhao1, Yingfang He1, Biao Peng1

1Department of Neurosurgery, Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, 510095, China

2State Key Laboratory of Respiratory Disease, The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China

3Department of Physiology, School of Basic Science, Guangzhou Medical University, Guangzhou, Guangdong, 510182, China

4Guangdong Provincial Hospital of TCM Breast Department, Guangzhou, Guangdong, 510006, China

*These authors have contributed equally to this work

Correspondence to:

Biao Peng, email: [email protected]

Keywords: glioma, miR-200b, LDHA, proliferation, metabolism

Received: December 04, 2015 Accepted: June 04, 2016 Published: June 27, 2016

ABSTRACT

Lactate dehydrogenase A (LDHA) is involved in various cancers. In this study, we investigated the expression and function of LDHA in glioma. We found that LDHA was up-regulated in glioma samples. Furthermore, we found that overexpression of LDHA promoted proliferation, invasion and glycolysis in glioma cells. Luciferase reporter assays confirmed that LDHA was a direct target of miR-200b. miR-200b was found to be down-regulated in glioma samples, which was inversely correlated with LDHA expression. Repression of LDHA by miR-200b suppressed the glycolysis, cell proliferation and invasion of glioma cells. These results provide evidence that miR-200b acts as a tumor suppressor in glioma through the inhibition of LDHA both in vitro and in vivo. Targeting LDHA through miR-200b could be a potential therapeutic strategy in glioma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10301

Publication Alerts

Research Papers:

miR-200b is a key regulator of tumor progression and metabolism targeting lactate dehydrogenase A in human malignant glioma

Abstract